Gould Gregory A purchased $5K of ACON
Gould Gregory A (CFO) purchased 3,388 shares of Aclarion, Inc. (ACON) at $1.44 on 2026-11-19.
Aclarion, Inc.
Aclarion is a healthcare technology company that uses magnetic resonance spectroscopy (MRS), proprietary biomarkers and software to help clinicians assess pain in spinal discs and inform treatment decisions. Its initial focus is chronic discogenic low back pain, particularly surgical planning. The company’s NOCISCAN platform analyzes MRS data from compatible MRI scanners and sends clinicians a report identifying discs as painful or not. The platform includes NOCICALC, which processes spectroscopy data and calculates biomarkers, and NOCIGRAM, which presents the results in a diagnostic report. Aclarion also provides a data-transfer platform for sending exam data to its cloud-based processing system. Aclarion makes money by marketing and selling its NOCISCAN post-processor software products. Its technology is compatible with certain SIEMENS and PHILIPS scanner models. Aclarion is headquartered in Broomfield, Colorado.
No enriched coverage for $ACON in the last 7 days.
Gould Gregory A (CFO) purchased 3,388 shares of Aclarion, Inc. (ACON) at $1.44 on 2026-11-19.
Aclarion (ACON) revised its CLARITY trial enrollment criteria to expand the patient pool and accelerate enrollment, while maintaining scientific rigor. The changes were approved by most trial sites and are expected to improve enrollment consistency and real-world applicability. The company anticipates providing an enrollment update by year-end 2026, with the trial timeline remaining unchanged. ACON's stock closed at $2.35, up 2.40%.
Williams Amanda M purchased 5,857 shares of Aclarion, Inc. (ACON) at $2.73 on 2026-08-17.
Recent ACON coverage spans insider activity, financial news and technology.
In the last 30 days, ACON insiders filed 1 SEC Form 4 transaction — 1 purchase ($5K) and no sales. The most active reporter was Gould Gregory A, CFO, with 1 filing.
Small insider purchase may create modest buying pressure.
The enrollment change is expected to increase patient flow and may improve trial timelines, supporting the stock.
Small insider buy may signal confidence but limited market impact due to modest size.
This is an insider open-market buy by the CFO, which can be read as mild positive sentiment but is not a fundamental catalyst by itself.
This is a director open-market buy disclosed via Form 4, which can be mildly supportive for sentiment but is not a fundamental catalyst by itself.
AlphAI scores every news story that mentions ACON with an AI model for sentiment and relevance, and aggregates insider trades from Aclarion, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Gould Gregory A (CFO) purchased 3,388 shares of Aclarion, Inc. (ACON) at $1.44 on 2026-11-19.
Aclarion (ACON) revised its CLARITY trial enrollment criteria to expand the patient pool and accelerate enrollment, while maintaining scientific rigor. The changes were approved by most trial sites and are expected to improve enrollment consistency and real-world applicability. The company anticipates providing an enrollment update by year-end 2026, with the trial timeline remaining unchanged. ACON's stock closed at $2.35, up 2.40%.
Williams Amanda M purchased 5,857 shares of Aclarion, Inc. (ACON) at $2.73 on 2026-08-17.
Gould Gregory A (CFO) purchased 10,000 shares of Aclarion, Inc. (ACON) at $2.45 on 2026-08-14.
Bond Ryan purchased 21,122 shares of Aclarion, Inc. (ACON) at $2.37 on 2026-08-13.
Wesemann William purchased 2,150 shares of Aclarion, Inc. (ACON) at $2.34 on 2026-08-13.
Neal David K purchased 7,500 shares of Aclarion, Inc. (ACON) at $2.40 on 2026-08-13.
Ness Brent (Chief Executive Officer) purchased 5,234 shares of Aclarion, Inc. (ACON) at $2.31 on 2026-08-13.
Aclarion, Inc. (Nasdaq: ACON) said the USPTO issued a Notice of Allowance for a patent application covering “Multi-Voxel Prescription for Lumbar Disc Evaluation,” aimed at improving MR spectroscopy voxel positioning in its Nociscan workflow. The company said the claims are intended to reduce repeat scans and variability across sites, extending its IP portfolio of 65+ patents worldwide.
Aclarion (Nasdaq: ACON) published a CEO shareholder letter updating progress in H1 2026. The company cited 141% YoY and 71% sequential scan volume growth, U.K. reimbursement momentum, a U.S. Market Access Program with PRIA Healthcare, and continued CLARITY trial site expansion. It reported $16.3M cash and no debt as of June 30, 2026.